Welcome to our dedicated page for Option Care Health news (Ticker: OPCH), a resource for investors and traders seeking the latest updates and insights on Option Care Health stock.
News about Option Care Health, Inc. (OPCH) centers on its role as the nation’s largest independent provider of home and alternate site infusion services and on its regular financial and corporate updates. The company issues detailed quarterly earnings releases, often accompanied by Form 8-K filings, that cover net revenue, net income, earnings per share, and non-GAAP metrics such as Adjusted EBITDA, Adjusted net income and Adjusted diluted EPS.
Investors following OPCH news will see announcements of preliminary and final quarterly and full-year financial results, as well as updated financial guidance ranges for net revenue, Adjusted EBITDA and Adjusted diluted earnings per share. These releases typically include management commentary on performance, cash flow from operations, stock repurchase activity and capital structure developments.
Option Care Health also uses news releases to communicate capital allocation decisions, such as expansions of its share repurchase program authorization, and to describe amendments to its credit agreements that affect term loans and revolving credit facilities. SEC Form 8-K filings referenced in the news provide additional detail on these material definitive agreements and financial obligations.
Corporate governance and leadership changes are another recurring news theme. For example, the company has announced a Chief Financial Officer transition, outlining the incoming CFO’s background, compensation arrangements and the outgoing CFO’s advisory role. News items also highlight Option Care Health’s participation in major healthcare and finance conferences, including events hosted by J.P. Morgan, UBS, Jefferies, Deutsche Bank and Bank of America, with webcasts and presentation materials made available to investors.
In addition, Option Care Health appears in partner company releases, such as Quince Therapeutics’ announcements of a strategic relationship for specialty infusion therapy support. These items describe how Option Care Health’s national network of specialty pharmacies and ambulatory infusion suites may be used to administer specific infused therapies, particularly in rare disease indications. For ongoing coverage of these financial, strategic and operational developments, OPCH news on this page aggregates company press releases, partner announcements and related disclosures.
Quince Therapeutics (Nasdaq: QNCX) announced significant progress in Q2 2025, highlighted by the completion of enrollment in its pivotal Phase 3 NEAT clinical trial for A-T treatment. The trial enrolled 105 participants, with topline results expected in Q1 2026. The company secured financing that brought its cash position to $34.7 million, providing runway through Phase 3 results into Q2 2026.
Key financial results include R&D expenses of $6.6 million, G&A expenses of $3.3 million, and a net loss of $16.1 million ($0.34 per share). Quince entered a strategic partnership with Option Care Health for U.S. commercial launch support and closed a premium-priced private placement led by Nantahala Capital, generating $11.5 million in upfront proceeds with potential additional proceeds of up to $10.4 million from warrants.
Quince Therapeutics (Nasdaq: QNCX) has established a strategic partnership with Option Care Health (Nasdaq: OPCH) for the commercial development and launch of its lead asset, encapsulated dexamethasone sodium phosphate (eDSP) in the United States.
Option Care Health will provide nationwide specialty pharmacy and infusion services through its network of 90+ pharmacies and 180+ ambulatory infusion suites. The partnership aims to enhance access to eDSP treatment for patients with Ataxia-Telangiectasia (A-T), with potential expansion to treat Duchenne muscular dystrophy (DMD).
The collaboration includes comprehensive services such as logistics management, patient registration, hub support, clinician-delivered services, and data reporting to support eDSP's commercial launch, pending positive study results and regulatory approval.
Option Care Health (Nasdaq: OPCH), the largest independent provider of home and alternate site infusion services, reported strong Q2 2025 financial results. The company achieved net revenue of $1.42 billion, up 15.4% year-over-year, with net income of $50.5 million.
Key financial metrics include gross profit of $269.0 million (19.0% of revenue), Adjusted EBITDA of $114.0 million (up 5.2%), and diluted EPS of $0.31. The company repurchased approximately $50.0 million of stock during Q2.
Option Care Health updated its FY2025 guidance, projecting revenue of $5.50-5.65 billion, adjusted EPS of $1.65-1.72, and adjusted EBITDA of $465-475 million. The company expects cash flow from operations of at least $320 million.
Option Care Health (NASDAQ: OPCH), the largest independent provider of home and alternate site infusion services in the US, has scheduled its Q2 2025 earnings release for July 30, 2025, before market opening. The company will host a conference call with management at 8:30 a.m. ET on the same day to discuss the results.
Investors can pre-register for the conference call through a provided link, and a live audio webcast will be available on the company's investor relations website. A replay of the call will be accessible for approximately 90 days after the event.
Option Care Health (NASDAQ: OPCH), the largest independent provider of home and alternate site infusion services in the US, has announced its participation in three major upcoming investor conferences in May and June 2025:
- Bank of America Healthcare Conference in Las Vegas (May 13, 2025, 11:00am ET)
- William Blair 45th Annual Growth Stock Conference in Chicago (June 3, 2025, 12:20pm ET)
- Goldman Sachs 46th Annual Healthcare Conference in Miami (June 9, 2025, 2:00pm ET)
The company, which employs over 8,000 team members including 5,000+ clinicians, operates across all 50 states providing infusion services for patients with acute and chronic conditions. Webcasts and presentation materials will be available at investors.optioncarehealth.com.
Option Care Health reported strong Q1 2025 financial results, with net revenue reaching $1.33 billion, up 16.3% from Q1 2024. The company, America's largest independent provider of home and alternate site infusion services, saw its gross profit rise 10.3% to $263.1 million.
Key financial highlights include:
- Net income of $46.7 million, with diluted earnings per share of $0.28
- Adjusted EBITDA increased 13.7% to $111.8 million
- Cash used in operations improved to $7.2 million from $68.8 million in Q1 2024
- Company repurchased approximately $100 million of stock
The company updated its 2025 guidance, projecting net revenue of $5.4-5.6 billion and adjusted EBITDA of $455-470 million. With over 8,000 team members including 5,000+ clinicians, Option Care Health continues to expand patient access across all 50 states.
Option Care Health (NASDAQ: OPCH), the nation's largest independent provider of home and alternate site infusion services, has scheduled its first quarter 2025 financial results announcement for Tuesday, April 29, 2025, before market opening. The company will host a conference call at 8:30 a.m. E.T. on the same day to discuss the results.
Investors can pre-register for the conference call through a provided link, and an audio webcast will be available at investors.optioncarehealth.com. A replay of the call will be accessible via webcast for approximately 90 days after the event.
Option Care Health (NASDAQ: OPCH) has released its Q4 and full-year 2024 financial results, showing strong revenue growth but mixed profitability metrics. Q4 2024 highlights include net revenue of $1,346.4M (up 19.7% YoY), net income of $60.1M, and adjusted EBITDA of $121.6M (up 8.9% YoY).
Full-year 2024 performance showed net revenue of $4,998.2M (up 16.2% YoY), though net income decreased to $211.8M from $267.1M in 2023. The company's gross profit margin declined to 20.3% from 22.8% in 2023.
For 2025 guidance, Option Care Health projects net revenue of $5.3B-$5.5B, adjusted EBITDA of $450M-$470M, and adjusted EPS of $1.59-$1.69. The company repurchased approximately $90.0M of stock in Q4 2024.
Option Care Health (NASDAQ: OPCH) released preliminary Q4 and full-year 2024 results, along with 2025 guidance. For Q4 2024, the company expects net revenue of $1.34-1.35B (19.2-20.1% growth), net income of $56.8-60.9M, and adjusted EBITDA of $118.7-121.7M.
Full-year 2024 projections include net revenue of $4.99-5.00B (16.0-16.2% growth), net income of $208.5-212.6M, and cash flow from operations exceeding $300M. For 2025, OPCH forecasts net revenue of $5.2-5.4B and adjusted EBITDA of $445-465M, noting a $60-70M negative gross profit impact from Stelara pricing adjustments.
The company also announced a new $500 million stock repurchase program after completing its previous $90M buyback in Q4 2024. The program has no expiration date and allows for various repurchase methods including open market purchases and block trades.
Option Care Health (OPCH), the largest independent provider of home and alternate site infusion services in the United States, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The event will take place in San Francisco, with Option Care Health scheduled to present on Monday, January 13, 2025, at 1:30pm PT.
The company, which employs over 7,500 team members including more than 4,500 clinicians, operates across all 50 states, providing care for patients with acute and chronic conditions. Interested parties can access the webcast and presentation materials through the company's investor relations website at investors.optioncarehealth.com.